Imaging Study Using a Radiotracer to Detect Demyelination in Brain and Spinal Cord
Tests a radioactive scan tracer, 18F 3F4AP, in healthy adults and people with demyelinating conditions.
Plain-language title generated from the registry record
Registry title: Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Key facts
- Where
- New Haven, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06999434, who can take part
Where in United States
- Yale University PET CenterNew Haven, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yale University
- Trial code
- NCT06999434
- Record updated
- 9 September 2026
- Original description
The overall objective is to obtain an assessment of the pharmacokinetics of [18F]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).Read full original descriptionShow less
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
The overall objective is to obtain an assessment of the pharmacokinetics of [18F]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Inclusion:; Male and Female subjects must be ≥18 and <90 years of age; Able to understand and provide informed consent prior to study procedures; Must be in good health; Exclusion:; Less than 18 years of age; Pregnant or breastfeeding; Any significant systemic illness or unstable medical condition; Pre-existing medical conditions or claustrophobic reactions; Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months); History of a bleeding disorder or are currently taking anticoagulants.